User login
Key clinical point: Gleason scores within grade group 4 prostate cancer were associated with biochemical recurrence, but not cancer-specific mortality or all-cause mortality.
Major finding: Gleason score (GS) 5 + 3 was associated with significantly higher rates of GS upgrading in radical prostatectomy (RP) specimens than either GS 3 + 5 or GS 4 + 4.
Study details: The data come from a retrospective review of 1,791 adults with grade 4 prostate cancer, including 190 with Gleason score (GS) 3 + 5; 1,557 with GS 4 + 4; and 44 with GS 5 + 3).
Disclosures: The study was funded in part by the Medical University of Vienna. The researchers had no financial conflicts to disclose.
Source: Mori K et al. Ann Surg Oncol. 2021 Jun 11. doi: 10.1245/s10434-021-10257-x.
Key clinical point: Gleason scores within grade group 4 prostate cancer were associated with biochemical recurrence, but not cancer-specific mortality or all-cause mortality.
Major finding: Gleason score (GS) 5 + 3 was associated with significantly higher rates of GS upgrading in radical prostatectomy (RP) specimens than either GS 3 + 5 or GS 4 + 4.
Study details: The data come from a retrospective review of 1,791 adults with grade 4 prostate cancer, including 190 with Gleason score (GS) 3 + 5; 1,557 with GS 4 + 4; and 44 with GS 5 + 3).
Disclosures: The study was funded in part by the Medical University of Vienna. The researchers had no financial conflicts to disclose.
Source: Mori K et al. Ann Surg Oncol. 2021 Jun 11. doi: 10.1245/s10434-021-10257-x.
Key clinical point: Gleason scores within grade group 4 prostate cancer were associated with biochemical recurrence, but not cancer-specific mortality or all-cause mortality.
Major finding: Gleason score (GS) 5 + 3 was associated with significantly higher rates of GS upgrading in radical prostatectomy (RP) specimens than either GS 3 + 5 or GS 4 + 4.
Study details: The data come from a retrospective review of 1,791 adults with grade 4 prostate cancer, including 190 with Gleason score (GS) 3 + 5; 1,557 with GS 4 + 4; and 44 with GS 5 + 3).
Disclosures: The study was funded in part by the Medical University of Vienna. The researchers had no financial conflicts to disclose.
Source: Mori K et al. Ann Surg Oncol. 2021 Jun 11. doi: 10.1245/s10434-021-10257-x.